aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
Returns on capital
aTyr Pharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-109.8%
avg -75.0%
ROIC
-96.5%
avg -61.6%
ROA
-78.7%
avg -54.4%
Analysis
ROA is currently the strongest return metric at -78.7% versus its period average of -54.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sanjay S. Shukla | President, Chief Executive Officer & Director | USD 861.05K | 54 | — | — |
Jill Broadfoot | Chief Financial Officer | USD 596.23K | 64 | — | — |
Nancy E. Denyes Krueger | General Counsel & Corporate Secretary | USD 571.16K | 58 | — | — |
Leslie Nangle | Vice President of Research | — | — | — | — |
Ashlee Dunston | Director of Investor Relations & Corporate Communications | — | — | — | — |
Dalia R. Rayes | Head of Commercial, Global Efzofitimod Franchise | — | — | — | — |
Peter Villiger | Vice President of Corporate Development | — | — | — | — |
Danielle Campbell | Vice President of Human Resource | — | — | — | — |
Compensation is shown in the reported currency; data updated Aug 8, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$49,630.00
Sells
3
$6,267.01
Net Transaction Value
+$43,362.99
Net buying
Most Active
SCHIMMEL PAUL
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 27, 26May 27, 2026 | SCHIMMEL PAUL Indirect | Buy | $49.6K$49,630.00 |
| Feb 4, 26Feb 4, 2026 | DENYES NANCY Direct | Sell | $1.1K$1,091.28 |
| Feb 4, 26Feb 4, 2026 | Broadfoot Jill Marie Direct | Sell | $1.5K$1,520.61 |
| Feb 4, 26Feb 4, 2026 | Shukla Sanjay Direct | Sell | $3.7K$3,655.12 |
Summary
Insiders reported 1 buys worth $49,630.00 and 3 sells worth $6,267.01 over the last 12 months. That adds up to net buying of $43,362.99. SCHIMMEL PAUL was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -73.7% | +293.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -73.7% over three years. Forward estimates point to Revenue at +293.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does aTyr Pharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ATYR's management, answered from reported figures.
Who manages ATYR?
aTyr Pharma, Inc. (ATYR) lists 8 active executives. The top listed executive is Leslie Nangle, Vice President of Research.
Are ATYR insiders buying or selling?
Recent insider activity shows net buying of $7.65M.
Continue the stock analysis
Jump to another research area for this company.